This Week in Oncology — Jul 9, 2026

Editor's Pick: Ensartinib in Resected-Positive Non-Small-Cell Lung Cancer (The New England journal of medicine, 2026)
Welcome to This Week in Oncology. This week we are covering four notable papers spanning novel therapeutic boundaries in thoracic oncology, the limits of aggressive regional interventions in gastric cancer, and the evolving systemic landscape of advanced prostate cancer. Let's dive in.
This week's papers:
• Ensartinib in Resected-Positive Non-Small-Cell Lung Cancer — The New England journal of medicine 2026 (pubmed.ncbi.nlm.nih.gov/42418775)
• Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42419336)
• Lung Transplant for Refractory Lung-Limited Stage IV Non-Small Cell Lung Cancer — JAMA 2026 (pubmed.ncbi.nlm.nih.gov/42418196)
• Advances in systemic therapies for advanced prostate cancer — BMJ 2026 (pubmed.ncbi.nlm.nih.gov/42419784)
Listen at AudioScholar (audioscholar.cc/episode/rz9q9z77ck)